Vietnam's life sciences sector is growing as the country becomes an increasingly important market for pharmaceuticals and clinical research. The Drug Administration of Vietnam (DAV) under MOH is modernizing drug registration processes, and Vietnam's large population provides a significant base for clinical trials. AI applications in drug discovery, clinical trial optimization, and pharmacovigilance are gaining traction as Vietnamese research institutions like VNU and the National Institute of Hygiene and Epidemiology expand their AI capabilities.
Vietnam's pharmaceutical market is still dominated by generic drugs, with limited domestic R&D investment that could leverage AI for drug discovery. Clinical trial infrastructure is developing but lags behind regional leaders like Singapore and South Korea. MOH's drug registration process is lengthy, and the regulatory pathway for AI-assisted drug development is undefined. Biological sample and clinical data management faces quality consistency issues across research sites, and the talent pool for computational biology and bioinformatics is small.
DAV under MOH regulates pharmaceuticals under the Pharmacy Law 2016 and Decree 54/2017 on drug registration. Clinical trials require Ethics Committee approval and MOH authorization under Circular 29/2018. Vietnam's accession to PIC/S (Pharmaceutical Inspection Co-operation Scheme) raises GMP standards. Biological data handling falls under Decree 13/2023's sensitive data provisions, and the Biodiversity Law 2008 governs genetic resource access relevant to AI-driven biotech research.
We understand the unique regulatory, procurement, and cultural context of operating in Vietnam
Vietnam's first comprehensive data protection law effective July 2024. Requires consent for personal data processing, notification of breaches, and data localization for sensitive categories. AI systems collecting personal data must comply with Ministry of Public Security regulations.
Requires foreign tech companies to store user data in Vietnam and establish local presence. Applies to AI platforms serving Vietnamese users. Mandates cooperation with government requests for data access.
Cybersecurity Law requires critical data (personal data, data affecting national security) to be stored in Vietnam. Banking data must remain in-country per State Bank of Vietnam (SBV) regulations. Foreign cloud providers must have Vietnam data centers or use local partners. Decree 13/2023 reinforces data localization requirements.
State-owned enterprises (SOEs) dominate economy with formal procurement requiring local partnership. Decision cycles 6-12 months with Communist Party approval for large projects. Private sector (Vingroup, FPT, Viettel) faster with 3-6 month cycles. Personal relationships and government connections critical. Budget approvals centralized at Ministry level for SOEs. Pilot budgets (500M-2B VND) approved at director level.
Government supports digital transformation through Project 06 (digital identity) and national digital transformation program. Ministry of Labour provides vocational training subsidies. Limited direct AI subsidies but growing under National Strategy on AI Development to 2030. State capital supports SOE technology adoption. Tax incentives for high-tech enterprises.
Vietnamese language training delivery essential - English proficiency lower than Singapore/Philippines. Communist Party influence requires government relationship management. Confucian values emphasize hierarchy and collective harmony. 'Saving face' culture requires diplomatic feedback delivery. Relationship building through shared meals and social events. North-South cultural differences (Hanoi vs Ho Chi Minh City) require localization.
Explore articles and research about AI implementation in this sector and region
Article
A guide to the best AI courses for Vietnamese companies in 2026. Corporate workshops in Ho Chi Minh City and Hanoi, government-supported programmes, and online options.
Article
Vietnam's Law on Artificial Intelligence, effective March 2026, is the first standalone binding AI law in Southeast Asia. It introduces risk-based classification, registration requirements, and penalties up to VND 2 billion for non-compliance.
Article
Navigate the complex landscape of AI regulations across Asia Pacific. From Singapore's AI Verify to Indonesia's PDP Law, understand compliance requirements across 6 key markets.
Article
Track 2026 AI regulatory changes across Singapore, Malaysia, Indonesia, and Hong Kong including enforcement trends, new guidance, and upcoming legislation.
Our team has trained executives at globally-recognized brands
YOUR PATH FORWARD
Every AI transformation is different, but the journey follows a proven sequence. Start where you are. Scale when you're ready.
ASSESS · 2-3 days
Understand exactly where you stand and where the biggest opportunities are. We map your AI maturity across strategy, data, technology, and culture, then hand you a prioritized action plan.
Get your AI Maturity ScorecardChoose your path
TRAIN · 1 day minimum
Upskill your leadership and teams so AI adoption sticks. Hands-on programs tailored to your industry, with measurable proficiency gains.
Explore training programsPROVE · 30 days
Deploy a working AI solution on a real business problem and measure actual results. Low risk, high signal. The fastest way to build internal conviction.
Launch a pilotSCALE · 1-6 months
Roll out what works across the organization with governance, change management, and measurable ROI. We embed with your team so capability transfers, not just deliverables.
Design your rolloutITERATE & ACCELERATE · Ongoing
AI moves fast. Regular reassessment ensures you stay ahead, not behind. We help you iterate, optimize, and capture new opportunities as the technology landscape shifts.
Plan your next phaseVietnam's DAV does not yet have specific guidelines for AI in drug discovery or development. AI-assisted drug candidates must follow standard registration under the Pharmacy Law 2016 and Decree 54/2017. Clinical trials involving AI-optimized compounds require standard MOH Ethics Committee and regulatory approvals. Early engagement with DAV is advisable as the agency develops its approach to AI in pharmaceutical development.
Vietnam is becoming more attractive for clinical trials due to its large, treatment-naive population and lower costs. MOH has simplified some clinical trial procedures, and institutions like Bach Mai Hospital and University Medical Center HCMC conduct international-standard trials. AI tools for patient recruitment, protocol optimization, and real-world evidence generation are increasingly relevant as Vietnam's clinical trial volume grows.
Let's discuss how we can help you achieve your AI transformation goals.
